Tissue site markers for in vivo imaging

ABSTRACT

The invention is directed biopsy site markers and methods of marking a biopsy site, so that the location of the biopsy cavity is readily visible by conventional imaging methods, particularly by ultrasonic imaging. The biopsy site markers of the invention have high ultrasound reflectivity, presenting a substantial acoustic signature from a small marker, so as to avoid obscuring diagnostic tissue features in subsequent imaging studies, and can be readily distinguished from biological features. The several disclosed embodiments of the biopsy site marker of the invention have a high contrast of acoustic impedance as placed in a tissue site, so as to efficiently reflect and scatter ultrasonic energy, and preferably include gas-filled internal pores. The markers may have a non-uniform surface contour to enhance the acoustic signature. The markers have a characteristic form which is recognizably artificial during medical imaging. The biopsy site marker may be accurately fixed to the biopsy site so as to resist migration from the biopsy cavity when a placement instrument is withdrawn, and when the marked tissue is subsequently moved or manipulated.

RELATED APPLICATIONS

The present application is a Continuation-In-Part of U.S. patentapplication Ser. No. 09/241,936, filed Feb. 2, 1999, and aContinuation-In-Part of U.S. patent application Ser. No. 09/343,975,filed Jun. 30, 1999. Each of the above referenced patent applications isincorporated by reference herein and the benefit of the filing date ofeach application is hereby claimed under 35 U.S.C. § 1.20.

BACKGROUND OF THE INVENTION

In diagnosing and treating certain medical conditions, it is oftendesirable to perform a biopsy, in which a specimen or sample of thesuspicious tissue is removed for pathological examination, tests andanalysis. As is known, obtaining a tissue sample by biopsy and thesubsequent examination are typically employed in the diagnosis ofcancers and other malignant tumors, or to confirm that a suspectedlesion or tumor is not malignant. The information obtained from thesediagnostic tests and/or examinations is frequently used to devise atherapeutic plan for the appropriate surgical procedure or other courseof treatment.

In many instances, the suspicious tissue to be sampled is located in asubcutaneous site, such as inside a human breast. Such removal of tissuesamples may be accomplished by open surgical technique, or through theuse of a specialized biopsy instrument and techniques. To minimizesurgical intrusion into patient's body, it is often desirable to inserta small instrument, such as a biopsy needle, into the body forextracting the biopsy specimen while imaging the procedure usingfluoroscopy, ultrasonic imaging, x-rays, MRI or any other suitable formof imaging technique. Examination of tissue samples taken by biopsy isof particular significance in the diagnosis and treatment of breastcancer. In the ensuing discussion, the biopsy and treatment sitedescribed will generally be the human breast, although the invention issuitable for marking biopsy sites in other parts of the human and othermammalian body as well.

Periodic physical examination of the breasts and mammography areimportant for early detection of potentially cancerous lesions. Inmammography, the breast is compressed between two plates whilespecialized x-ray images are taken. If an abnormal mass in the breast isfound by physical examination or mammography, ultrasound may be used todetermine whether the mass is a solid tumor or a fluid-filled cyst.Solid masses are usually subjected to some type of tissue biopsy todetermine if the mass is cancerous.

If a solid mass or lesion is large enough to be palpable, a tissuespecimen can be removed from the mass by a variety of techniques,including but not limited to open surgical biopsy, a technique known asFine Needle Aspiration Biopsy (FNAB) and instruments characterized as“vacuum assisted large core biopsy devices”.

If a solid mass of the breast is small and non palpable (e.g., the typetypically discovered through mammography), a relatively new biopsyprocedure known as stereotactic needle biopsy may be used. In performinga stereotactic needle biopsy of a breast, the patient lies on a specialbiopsy table with her breast compressed between the plates of amammography apparatus and two separate x-rays or digital video views aretaken from two different points of view. A computer calculates the exactposition of the lesion as well as depth of the lesion within the breast.Thereafter, a mechanical stereotactic apparatus is programmed with thecoordinates and depth information calculated by the computer, and suchapparatus is used to precisely advance the biopsy needle into the smalllesion. Depending on the type of biopsy needle(s) used, thisstereotactic technique may be used to obtain cytologic specimens, e.g.,obtained through FNAB or it may be used to obtain histologic specimense.g., obtained through coring needle biopsy. Usually at least fiveseparate biopsy specimens are obtained from locations around the smalllesion as well as one from the center of the lesion.

The available treatment options for cancerous lesions of the breastinclude various degrees of mastectomy or lumpectomy and radiationtherapy, as well as chemotherapy and combinations of these treatments.However, radiographically visible tissue features, originally observedin a mammogram, may be removed, altered or obscured by the biopsyprocedure. In order for the surgeon or radiation oncologist to directsurgical or radiation treatment to the precise location of the breastlesion several days or weeks after the biopsy procedure was performed,it is desirable that a biopsy site marker be placed in or on thepatient's body to serve as a landmark for subsequent location of thelesion site. While current radiographic type markers may persist at thebiopsy site, an additional mammography generally must be performed atthe time of follow up treatment or surgery in order to locate the siteof the previous surgery or biopsy. In addition, once the site of theprevious procedure is located using mammography, the site must usuallybe marked with a location wire which has a barb on the end which isadvanced into site of the previous procedure. The barb is meant to fixthe tip of the location wire with respect to the site of the previousprocedure so that the patient can then be removed from the confinementof the mammography apparatus and the follow-up procedure performed.However, as the patient is removed from the mammography apparatus, orotherwise transported the position of the location wire can change orshift in relation to the site of the previous procedure. This, in turn,can result in follow-up treatments being misdirected to an undesiredportion of the patient's tissue.

As an alternative or adjunct to radiographic imaging, ultrasonic imagingand visualization techniques (herein abbreviated as “USI”) can be usedto image the tissue of interest at the site of interest during asurgical or biopsy procedure or follow-up procedure. USI is capable ofproviding precise location and imaging of suspicious tissue, surroundingtissue and biopsy instruments within the patient's body during aprocedure. Such imaging facilitates accurate and controllable removal orsampling of the suspicious tissue so as to minimize trauma tosurrounding healthy tissue. For example, during a breast biopsyprocedure, the biopsy device is often imaged with USI while the deviceis being inserted into the patient“s breast and activated to remove asample of suspicious breast tissue. As USI is often used to image tissueduring follow-up treatment, it may be desirable to have a marker,similar to the radiographic markers discussed above, which can be placedin a patient's body at the site of a surgical procedure and which arevisible using USI. Such a marker enables a follow-up procedure to beperformed without the need for traditional radiographic mammographyimaging which, as discussed above, can be subject to inaccuracies as aresult of shifting of the location wire as well as being tedious anduncomfortable for the patient.

SUMMARY OF THE INVENTION

The invention is directed generally to devices and methods of marking abiopsy site, so that the location of the biopsy cavity is readilyvisible by ultrasonic imaging, as well as by conventional imagingmethods, such as x-rays. The biopsy site marker of the invention is apersistent marker which may be identified and located by ultrasoundvisualization.

The biopsy site markers of the invention have a body conformation toenhance acoustical reflective signature or signal. The body conformationmay include boundaries of high contrast of acoustic impedance to enhanceultrasound reflection. The markers are readily detected by USI andpresent a substantial acoustic signature from a marker with smallphysical dimensions or size. Because of the high acoustic reflectivityof the markers of the invention, the marker size may be reduced todimensions determined by the physical limits of the imaging systemitself, e.g., the ultrasound (US) beam width, without requiring a largeror excessive marker size to reflect sufficient US energy to benoticeable.

In one embodiment, the biopsy site markers of the invention have acharacteristic body shape which is recognizably artificial duringmedical imaging, so as to be readily distinguishable from biologicalfeatures within the marked tissue. In particular, the markers arereadily distinguishable in the various imaging procedures fromdiagnostically important tissue features, such as lines ofcalcifications which frequently are signs for a developing malignancy.The marker body shape may have one or more distinct features which maybe visualized in different marker orientations. The shape may correspondto a generally known symbol, so a to enhance recognition.

In another embodiment, the markers of the invention have a bodyconformation to enhance the acoustic signature or signal, so that thebody has high acoustic reflectivity when situated in tissue. Theacoustic reflective signature of the markers depends on a number offactors. The marker may comprise a composition which presents at leastone boundary of high contrast in acoustic impedance to incident USenergy, effectively reflecting the US energy to be received by theimaging system. Acoustic impedance (AI) of a material is equal to theproduct of the characteristic density (ρ) of the material and theacoustic velocity (c) in the material, (i.e., AI=ρ×c). As an incident USbeam encounters a boundary with a large change in acoustic impedance(e.g., at the marker surface or internal to the marker), much of the USenergy is effectively reflected.

Different types of tissue have a wide range of acoustical impedance, forexample lung tissue with high air content having low acousticalimpedance as compared to bone tissue having high mineral content.However, for uses such as biopsy site marking in typical mammalian softtissue of high aqueous content, the typical range of tissue acousticalimpedance is intermediate these extremes. The composition and bodyconformation of the markers of the invention may be selected so as toprovide boundaries of high contrast of acoustic impedance with respectto the particular tissue site of use.

In an embodiment of the invention, the marker may have a composition inwhich a base or matrix substance of the marker body (e.g., stainlesssteel) has an acoustic impedance substantially higher than the tissue atthe marked body site. For example, typical bio-compatible metalmaterials, such as stainless steel, titanium, platinum and the like,generally have acoustic impedance values in the range of 15 to more than30 times that of typical soft tissue of high aqueous or fatty content.The high acoustic impedance of the marker body base material relative tothe surrounding tissue presents a reflective interface to an incident USbeam.

A suitable marker body composition with acoustic impedance substantiallyhigher than the tissue at the marked body site is 316L stainless steel.Other alternative compositions, such as compositions of bio-compatiblemetals, ceramics, metal oxides or polymers, or composites or mixtures ofthese materials, may be suitable. The marker body may also beradio-opaque.

In another embodiment of the invention, the marker may have acomposition in which marker body includes one or more (preferably alarge plurality) of internal bounded spaces, such as voids, pores,discontinuities, inclusions, bubbles and the like. These internal spacespreferably contain or entrain air or other gases.

Air has an extremely low acoustic impedance relative to the marker bodybase or matrix substance. This is true even for matrix materials whichthemselves have acoustic impedance close to that of the surroundingtissue (e.g., some bio-compatible polymers). The marker body presentsinternal boundaries of high contrast in acoustic impedance, i.e., at theboundary between the matrix and each internal air-filled space. Themarker body thus presents plurality of reflective interfaces to anincident US beam.

Alternatively or in combination with to the materials of high acousticimpedance described above, a marker body with internal voids or airspaces may, if desired, comprise a matrix or base composition which hasan acoustic impedance close to that of the tissue at the marked bodysite, since the air or other gas within the internal spaces provides adramatic contrast to the matrix material. Suitable bio-compatiblematerials include polyethylene, polytetrafluoroethylene, PEBAX (made byAutochem Corp.), and the like.

The body matrix material can have a hydrophobic composition or betreated to be hydrophobic. The surface area bounding internal open-cellpores should be hydrophobic so as to resist the displacement of air orother gases in the pores by aqueous fluid from the surrounding tissue,particularly in the case of relatively large pore or space size.

In some embodiments of the invention, the markers can include surfacecharacteristics which enhance the acoustic signature and improvevisibility under US imaging, as opposed to a smooth, rounded bodysurface. In order to provide enhanced ultrasound imaging visibility fromall directions of US impingement, the biopsy marker can have a pluralityof reflective external surfaces. By making the surface of an objectlobulate, multifaceted or otherwise irregular, more reflective surfacesare created, and a brighter acoustic signature is achieved.

For example, a smooth solid sphere provides at least some reflectivesurface oriented in each direction, but the reflection is achieved overa small portion to the area of the sphere, thus producing anunremarkable acoustic signature. In contrast, an object of the samecomposition and average diameter as the sphere, but with a highlyirregular surface texture, a much brighter acoustic signature or signalis achieved. Thus, the by providing more reflective surfaces ofdiffering or random orientation, the markers appears brighter in USimaging.

The signal-enhancing body conformation may include non-smooth surfacetexture, such as a porous, frosted, matte, pitted, peened, or scratchedsurface texture, and the like. The body conformation may also include amulti-element surface contour, such as a faceted, multi-planar,lobulate, coiled, grooved, folded, or inlet surface contour, and thelike. Such external body conformations may be used in combination withone another and in combination with the internal discontinuities or airspaces described above.

The body length, diameter or other characteristic scale dimensions ofsome embodiments of the biopsy marker of the invention may be of a rangeof sizes. The optimum dimensions of the body will depend upon thespecific selected factors which influence acoustic signature asdescribed herein, such as material impedance, surface contours, surfacetexture, and internal conformation. In addition, the optimum size maydepend upon such factors as the type of ultrasound imaging/visualizationsystem used, its imaging resolution, the operating ultrasound frequency,and the biophysical nature of the tissue of interest.

The body dimensions may be selected so as to be large enough to providea distinct, recognizable marker image within the tissue biopsy site,when visualized under the particular imaging system and operatingconditions of use. The body dimensions may also be selected to be smallenough to avoid masking or obscuring diagnostically important tissuefeatures. Thus different marker dimensions may be selected to suitparticular biopsy site tissue types, and to suit particular known andfuture medical imaging equipment.

In terms of over-all size, it is desirable that the marker have at leastone dimension which is about as large as or greater than the beam widthof the USI system with which it is to be visualized. Typically, forcurrent USI systems, the marker will have at least one dimension ofabout 1 mm or greater, and preferably of at least about 1.5 mm.

In addition, for convenience in applying the marker to the tissue site,the specific marker dimensions and shape may be selected so as toaccommodate the dimensions of a particular known or novel biopsy needledevice or sampling apparatus, while still achieving a distinct andrecognizable marker image under medical imaging as placed at the tissuesite. By selecting a marker size and shape to fit within the internaldiameter of a biopsy needle or sampling device, the marker may beimplanted or applied to the biopsy cavity during the course of thebiopsy procedure, following sample recovery but prior to removal of thebiopsy device. For example, the marker of the invention may have a sizeand shape selected to permit application of the marker through thehollow interior space of a vacuum assisted large core biopsy device,such as is commercially available from Johnson and Johnson, EthiconEndosurgery Division. The small physical size of the markers of theinvention relative to their acoustic reflectivity permits fitting themarkers to a wide variety of biopsy devices.

In terms of the size of features, including external or internal pores,texture features, facets and the like, it is preferable that thesefeatures have a characteristic dimension approximately equal to orexceeding the wavelength of the US beam of the imaging system. Forexample, with current imaging systems, for a marker with internalair-filled pores, the pore size is typically from about 1 micrometer to100 micrometers and preferably from about 5 micrometers to 40micrometers, to provide high reflectivity of the incident US energy.

Optionally, some embodiments of the biopsy site marker of the inventionmay have elements which assist in accurately fixing the marker to thebiopsy site so as to resist migration from the biopsy cavity. Suchmigration can occur when a placement instrument is withdrawn, and whenthe marked tissue is subsequently moved or manipulated, as for examplewhen a breast is decompressed and removed from the mammographyapparatus. In one embodiment, one or more tissue engaging structures orhaptic elements are mounted or affixed to the main marker body, so as toresist movement or migration of the marker from the biopsy site in whichit has been implanted during use.

In another embodiment, the biopsy site marker may comprise apellet-shaped element which encapsulates the high impedance marker body,and assists in resisting migration. The encapsulating pellet may be of acomposition, such as gelatin, which is absorbed or dissipated over time,leaving the persistent marker body at the tissue site. In yet anotherembodiment, the marker body (and/or the optional encapsulating element)may include an adhesive component to cause the marker body (orencapsulating element) to adhere to adjacent tissue within the biopsysite.

A method of the invention for marking a tissue site of interest caninclude implanting one or more of the markers of the invention, such asone of the exemplary marker embodiments described herein, in or adjacentto a tissue site of interest, e.g., within a biopsy cavity. The markermay then be visualized in situ, such as for purposes of subsequentmedical and surgical procedures. The visualization may be by variousknown medical imaging systems and methods, and in particular may bevisualized by known USI systems.

Biopsy markers of the invention can be deposited in accordance with thevarious methods and techniques utilized in the state of the art. Onetechnique of applying the biopsy markers of the invention is to place ordeposit them in a biopsy cavity that is created with a vacuum assistedlarge core biopsy device. An applicator particularly suitable forinsertion of the biopsy site markers of the invention is describedbelow. However, it should be understood that the biopsy markers of theinvention can be used without the exemplary applicator device describedherein. The biopsy marker applicator disclosed in co-pending applicationSer. No. 09/343,975 filed Jun. 30, 1999, may be used to apply themarkers of the current invention to a biopsy site. The dimensional sizeof the applicator device (particularly the inside diameter) may beadjusted to correspond to a selected diameter or characteristicdimension of the biopsy site marker embodiment of the present invention.

These and other advantages of the invention will become more apparentfrom the following description when taken in conjunction with theaccompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a perspective view of a human breast partially cut away havinga lesion from which a biopsy specimen has been removed, and showing amarker applicator syringe and introduction cannula operativelypositioned for introduction of a biopsy site marker embodying featuresof the present invention into the cavity created by removal of thebiopsy specimen;

FIGS. 2A-2E show exemplary conformations and shapes of sintered orporous metal site marker embodiments of the invention, FIG. 2A showing asintered body having irregular pores, FIG. 2B showing a bubble-filledmarker body, FIG. 2C showing a cylindrical-shaped marker, FIG. 2Dshowing a cruciform-shaped marker and FIG. 2E showing a polyhedralshaped marker.

FIG. 3 shows a marker having the shape of a Greek letter.

FIG. 4 shows an example of the alternative coil-shaped embodiment of themarker of the invention;

FIG. 5 shows an example of the alternative spheriod embodiment of themarker of the invention;

FIG. 6 is a schematic view (scale exaggerated for clarity) of anexemplary biopsy tissue site, in this case a human breast, showing abiopsy cavity of the type obtained by a known type of vacuum assistedlarge core biopsy sampler device, into which a biopsy marker or markersembodying features of the invention are deposited by a marker applicatordevice inserted through the outer cannula of the large core biopsysampler.

FIG. 7 shows schematically an embodiment of the invention including oneor more haptic elements and/or an adhesive component, for resistingmigration of the marker within the tissue.

FIG. 8 shows schematically an embodiment of the invention including anencapsulating element and optional adhesive component, for resistingmigration of the marker within the tissue.

FIG. 9A is a schematic view of a biopsy sampler device at a tissue sitewith an alternative marker delivery system.

FIG. 9B is a perspective view of the petalled distal end of the deliverydevice shown in FIG. 9A.

FIG. 9C is a perspective view of the distal end of the delivery deviceshown in FIG. 9A with a marker exiting the petalled distal end.

FIG. 10 is a perspective view of an alternative marker having a gel bodywith a radiopaque collar disposed about the gel body.

DETAILED DESCRIPTION OF THE INVENTION

The following detailed description, and the accompanying drawings towhich it refers are provided for purposes of exemplifying andillustrating representative examples and embodiments of the inventiononly, and are not intended to limit the scope of the invention in anyway, and do not exhaustively illustrate and describe all possibleembodiments and configurations in which one or more features of thepresent invention may take physical form.

All patents and patent applications cited in this specification areherein incorporated by reference as if each individual patent or patentapplication were specifically and individually indicated to beincorporated by reference.

FIG. 1 shows the use and insertion into a biopsy site of any one of thebiopsy site marker embodiments of the invention described herein. FIG. 1is a perspective view of a human breast 2 having a lesion 3 from which abiopsy specimen has been removed, thereby forming a biopsy cavity 4within the lesion 3, into which a biopsy site marker 10 of the of thepresent invention is implanted. The figure shows an outer cannula 12with the distal end thereof operatively positioned within the biopsysite 4. The outer cannula 12 has been inserted percutaneously into thelesion 3 and a biopsy needle (not shown) has been passed through theouter cannula 12 and used to remove a biopsy specimen from the center ofthe lesion.

Syringe-like marker application device 13 includes a marker introductiontube or inner cannula 14. After removal of the biopsy needle (notshown), the marker introduction cannula 14 has been passed through theouter cannula 12 such that inner cannula distal end 14d is locatedwithin the biopsy cavity 4, the marker 10 being housed within cannula14. Piston 15 of marker applicator 13 has an extension 16 which passesthrough the interior of inner cannula 14. Upon depressing piston 15,extenuation 16 pushes marker 10 outward through an opening 17 in the tip14 d of inner cannula 14 into the cavity 4.

The outer cannula 12 may be an outer tube element of a conventionalvacuum assisted large core biopsy device, which has been left in placeto assist in site marker application following biopsy sample recovery.One example of a applicator syringe device 13 is described in furtherdetail below with respect to FIG. 5.

FIGS. 2A, 2B, 2C, 2D and 2E show exemplary internal conformations andshapes of the sintered or porous site marker embodiments of theinvention 20 a-20 e respectively.

FIGS. 2A and 2B show schematic cross sections of a alternative porous orsintered marker body embodiments. FIG. 2A is a cross section of asintered site marker embodiment 20 a. The matrix or base material 21encloses a plurality of irregular shaped pores 22 distributed within thebody 20 a, preferably throughout the body volume. The term “sintered”will be used to describe the porous body conformation, it being notedthat conventional methods of production other than sintering may beemployed to produce a material containing internal voids, pores,discontinuities, inclusions, bubbles and the like.

The pores 22 may be open celled, in which the pores 22 generallyintersect or communicate with one another and the marker body exterior,which may give the body surface 23 a pitted texture on the scale of thepore size. Alternatively, the pores may be closed celled, in which thepores 22 generally do not intersect one another or the exterior. In theevent that the pores 22 communicate with the marker exterior 23, thematrix material 21 is preferably hydrophobic (or treated to havehydrophobic surfaces) to resist displacement of air entrained in pores22.

The base or matrix composition 21 has may be of high acoustic impedancerelative to the surrounding tissue (not shown). Sintered metal materialmay be shaped and sintered from commercially available metallic powderscomprising a metal or mixtures of metals, using conventional sinteringand forming techniques to produce body of selected shaped, and selectedpore size and surface texture, so as to enhance acoustic reflectivity.The porosity of the sintered metal provides an irregular surface textureas well as internal voids. A suitable bio-compatible material issintered 316L stainless steel, and suitable sintered stainless steelstock is commercially available in various forms, for example from theMott Corporation. The sintered stock may be economically cut and shapedby conventional methods. Sintered stainless steel stock is commerciallyavailable with controlled pore size, selectable over a range of poresizes. The pores 22 of the sintered body 20 a may vary over a range ofpore sizes, and is typically from about 1 micrometer to 100 micrometersand preferably from about 5 micrometers to 40 micrometers.

In addition to sintered metal, alternative bio-compatible, impedancematerials may be included or substituted, such as ceramics, metaloxides, polymers or composites/mixtures of these materials, which may beconfigured to have a generally distributed internal porosity and poroussurface texture. Thus, the marker body 20 a may comprise a matrix orbase composition 21 which has an acoustic impedance close to that of thetissue at the marked body site, since the air or other gas within thepores or internal spaces 22 provides a dramatic contrast to the matrixmaterial 21. Suitable bio-compatible materials include polyethylene,polytetrafluoroethylene, PEBAX (made by Autochem Corp.), and the like.Such porous materials may be formed by conventional methods, such asheat bonding of polymer powders, extrusion and the like.

FIG. 2B is a schematic cross section of an alternative site markerembodiment 20 b. The matrix or base material 24 encloses a plurality ofinclusions, suspended particles or bubbles 25 distributed within thebody 20 b, preferably throughout the body volume. The inclusions 25 maybe low-density or gas-filled particles, such as foamed-in-place bubbles,micro-beads, expanded beads, and the like, which have an acousticimpedance substantially lower than the matrix material 24. The matrixmaterial 24 may as in the example of FIG. 2A.

FIGS. 2C and 2D show exemplary shapes of the sintered or porous sitemarker embodiments of the invention 20 c and 20 d respectively. FIG. 2Cshows schematically a cylindrical sintered marker 20 c. The marker 20 ccomprises a generally cylindrical body having a diameter d and length 1.The body may have diameter d of from 0.5 to 5 mm, and preferably about1.5 mm. The length l may be from about 1 diameters to about 10diameters, and preferably from about 5 to 7 diameters. This biopsy sitemarker produces a distinct, recognizable, marker image of artificialappearance when implanted at a depth of about 2 to 4 cm in human breasttissue, and visualized by a commercially available Accuson 128 USimaging system with an L7 transducer.

FIG. 2D illustrates a marker body 20 d having a polyhedral form ofmultiple intersecting flat surfaces 26, 27 and 28.

FIG. 2E shows a cruciform shaped marker 20 e having cruciformcross-section having four longitudinal fin-like portions 29, which maybe aligned at right angles to one another and joined at the longitudinalcentral axis 30 providing a selectable number of side facets (e.g.,hexagonal cross-section). Optionally, medial web portions 31 may spanlaterally and join between adjacent fins 29, the webs 31 preferablybeing aligned perpendicularly to the fins 29. In the example shown,there are four such web portions 31 positioned at about mid-length ofthe body 20 e, so that each fin 29 is joined by a pair of webs 31, oneon each side, to each adjacent fin. Thus, the planes of the intersectingfins and webs form a pattern of eight mutually-perpendicular “cornerreflectors” 32. The length l and characteristic cross-section dimensionc may be as described with respect to the embodiments of FIGS. 2C and2D.

FIG. 3 illustrates yet another alternative where the marker body isshaped to have the form, under ultrasound or radiological visualization,preferably both, of a familiar symbol or letter, to by easilyrecognizable as an artificial shape which is the lower-case Greek letterGamma (γ), which when visualized in a biopsy site bears a resemblance toa familiar breast-cancer-awareness symbol.

FIG. 4 shows schematically an alternative coil marker 30 of theinvention. The marker 30 comprises a generally helical coil-like bodyformed from one or more lengths of fine wire and/or fiber 31. The coil30 has a generally cylindrical overall form. As with the other biopsysite marker embodiments of the invention, the optimum dimensions of thecoil shaped marker embodiment will depend on such factors as the type ofvisualization system used, its imaging resolution, and the physicalnature of the biopsy tissue region. The coil length l and diameter d maybe of a range of sizes, selected so as to be large enough to provide adistinct, recognizable ultrasound marker image within the tissue biopsysite, and small enough to avoid masking or obscuring diagnosticallyimportant tissue features. For example, the coil diameter d may be from0.5 to 5 mm, and preferably about 1.5 mm. The coil length l is typicallyfrom about 1 coil diameters to about 10 coil diameters, and preferablyfrom about 5 to 7 coil diameters.

The helical turns of the coil provide a body surface contour including aouter helical groove 32 and inner helical groove 33 on the coil surfaces(more than one such groove for a multiple helix). The grooved coil bodysurface includes a plurality of lobes and crevices on the exterior ofthe coil which enhance acoustic reflectivity. In addition the similarlylobed internal surfaces of the coil provide additional reflectivity.Optionally, the coil may be given a “frosted” or textured surface, suchas by particle blasting in the manner of the spheroid marker describedabove. A uniform coil embodiment has a shape which is markedlyartificial in appearance under conventional visualization methods, andis not easily confused tissue features of biological origin.

The coil may comprise a fine wire 31 of a material of high acousticimpedance relative to the tissue of the site, and may optionally beradio-opaque. Suitable materials are biologically compatible metals,such as stainless steel, titanium, platinum, palladium, alloys thereofand the like. The coil may alternatively comprise a composite ofdifferent materials, such as a composite of metal and polymericmaterials. The coil may be wound about a central core of the same ordifferent composition. Coil stock of suitable material, helical form anddiameter is available commercially, and may be cut to a selected lengthby conventional means. A suitable material is 316 L stainless steelsurgical embolization coil currently used in arterial embolism repairprocedures, e.g., Cook 4 mm diameter embolization coil MWCE-25-2.5-4 of316L stainless steel and Dacron. Other suitable embolization coil stockis available in a range of coil diameters. This biopsy site markerproduces a distinct, recognizable marker image as implanted at a depthof about 2 to 4 cm in human breast tissue, when visualized by acommercially available Accuson 128 US imaging system with an L7transducer.

FIG. 5 shows schematically the alternative spheroid marker 40 of theinvention having a generally spherical body 40. Note that the porous orsintered marker embodiments of FIGS. 2A-2D may be spherical also.However, the embodiment of FIG. 5 is a non-porous example, and thebiopsy site marker 40 comprises a high acoustic impedance, biologicallycompatible material, such as 316 L stainless steel and titanium, orradiopaque metals such as platinum, palladium, or the like.Non-spherical shaped bodies may be used, however, metallic spheres ofsuitable materials are readily commercially available, and have a shapewhich is markedly artificial in appearance under conventionalvisualization methods, i.e., not easily confused tissue features ofbiological origin.

The generally spherical body may have a diameter d selected so as to belarge enough to provide a distinct, recognizable ultrasound marker imagewithin the tissue biopsy site, and small enough to avoid obscuringtissue features. As with the other biopsy site marker embodiments of theinvention, the optimum size of the sphere will depend on such factors asthe type of visualization system used, its imaging resolution, and thephysical nature of the biopsy tissue region. For example, the spherediameter d is typically be from about 1 mm to about 4 mm, and preferablyfrom about 1.5 mm.

The spherical body 40 may include a pitted, matte, peened or frostedsurface texture 41, which may be produced by conventional particleblasting or peening techniques. For example, the sphere may be blastedwith glass beads of about 100 micrometer diameter to produce a frostedsurface. In another example, the sphere may be blasted with aluminumoxide abrasive particles of about 25 micrometer diameter to produce afrosted surface. The frosted surface 41 thus produced provides enhancedacoustic reflectivity in comparison to the untreated, smooth sphere.Other conventional texturing, pitting or faceting methods mayalternatively be used to produce a frosted or irregular surface texture.

This biopsy site marker produces a distinct, recognizable marker imageof artificial appearance when implanted at a depth of about 2 to 4 cm inhuman breast tissue, and visualized by a commercially available Acuson128 US imaging system with an L7 transducer.

FIG. 6 shows schematically in cut-away section an exemplary markerapplicator device 50 configured to be operated in association with aconventional vacuum assisted large core biopsy device 6. The dimensionalsize of the applicator device (particularly the inside diameter) may beadjusted to correspond to the selected diameter or characteristicdimension of the biopsy site marker to be deposited. In this connectionit should be understood that the biopsy markers of the invention can beused without this applicator, and can be deposited in accordance withthe various methods and techniques utilized in the state of the art.

The applicator 50 comprises an elongated cylindrical body 52 which hasan outer diameter selected so that it fits, and may be inserted through,the outer cannula 7 of vacuum assisted large core biopsy device 6. Asshown in FIG. 6, the outer cannula 7 is inserted through the biopsyincision into the biopsy cavity 4 previously formed in the patient'stissue site 8, e.g., a human breast in the case of a breast biopsy.

The cylindrical body 52 has an interior cavity and a piston 54 that fitsand slides back and forth in the elongated cylindrical body 52. Theproximal end of the outer cannula 7 may be provided with rectangularlyshaped handle 56 the orientation of which indicates to the operator theorientation of the opening 9 provided in the distal end of the cannula7. The cylindrical body 52 may have an enlarged finger disk or handle 57at its outer (exterior to the patient) end which permits a user (notshown) to operate or move the piston 54 within the cylinder 52 ofapplicator 50. the orientation of the elongated finger disk 57 indicatesthe orientation of the opening 58 of body 53 adjacent its other, closedend 59 (internal within biopsy cavity). The opening 58 is configured toform a ramp in the side of the tube 52.

In this connection it should be understood that the selected dimensionsof the tube 52 are coordinated with the dimensions of the piston 54 andwith the cannula 7 of the vacuum assisted large core biopsy device 6,thus permitting the tube 52 to both fit within cannula 7 and to containone or more markers of the invention 10 within the inside diameter ofcylinder 52. The cylinder or tube 52 and the piston 54 may be made fromany appropriate medical grade plastic material, such as high densitypolyethylene or PEBAX, made by the Autochem Corporation.

In one method of implanting the biopsy markers 10 of the presentinvention, the tube 52 is loaded with one or more of markers 10. Themarkers 10 may be any of the embodiments of the invention describedabove, and is shown schematically as a cylindrical object. Optionally,in addition to the markers 10, pellets composed of various othermaterials may be inserted along with one of the embodiments of thebiopsy markers of the present invention described herein. For example,gelatin pellets of the type disclosed in our above referenced co-pendingapplication Ser. No. 09/343,975 may be inserted in conjunction with thebiopsy markers 10 of the present invention.

With the markers 10 in the tube 52 and the tube 52 and cannula 7inserted into the biopsy site 4, the opening 58 in the cylinder 52 ismoved into alignment with the opening or port 9 of the in the internalend of cannula 7 of biopsy sampler 6. The piston 54 is pressed inward bythe operator so that the marker or markers 10 are expelled from the tube52 through the ramp shaped opening 58 as the piston 54 is pushed intothe cylinder or tube 52. The markers 10 are thereby extruded throughopening 59 and port 9 into the biopsy cavity 4. The applicator 50 andbiopsy device 6 are subsequently withdrawn.

FIG. 7 shows schematically an alternative marker 60 of the inventionincluding one or more optional tissue-engaging or haptic elements 62 forresisting migration of the marker from the biopsy site. An exemplarycylindrical marker body 10 is shown, although each embodiment of thebiopsy site marker of the invention described above may optionallycomprises one or more such tissue engaging structures. The hapticelements 62 may comprise an wire-like material fixed to the marker body10 at the proximal haptic end 64 and extending outward from the markerbody 10. The haptic 62 may be looped back at its hook-like terminal end66.

The haptic 62 assists in resisting migration of the marker from thebiopsy cavity, during initial placement, i.e., it engages the adjacenttissue to resist being sucked back towards the applicator when theapplicator is withdrawn. The haptic also resists migration during latermovement, flexure or manipulation of the tissue surrounding the biopsysite, such as when a patient's breast is decompressed upon removal froma mammography device. Optionally, the marker body 10 may include anadhesive component 68 coated onto its surface to cause the marker bodyto adhere to adjacent tissue within the biopsy site.

FIG. 8 shows schematically the alternative marker 70 of the inventionincluding an encapsulating element 72 and optional adhesive layer orcomponent 74, for resisting migration of the marker within the tissue.An exemplary cylindrical marker body 10 is shown, although each of thebiopsy site marker of the invention described above may optionallycomprise a pellet-shaped encapsulating element.

The pellet-shaped encapsulating element 72 is disposed surrounding themarker body 10 and may fully or partially enclose the marker body. Theencapsulating element 72 may be of lower impedance than the metallicmarker body 10. Suitable materials are gelatin or reconstituted collagenmaterial, polymers, or mixtures or composites thereof. An optionaladhesive component 74 is shown coating the external surface of theencapsulating element, but may be included within the composition theencapsulating element 72.

FIG. 9A illustrates an alternative device 80 for delivering markers to abiopsy site which includes an elongated tube 81, a handle 82 on thetubes proximal end and a closed distal end having a plurality of leafsor petals 83 as shown in more detail in FIG. 9B. As shown in FIG. 9C,the petals 83 open up to allow a marker 84 to be discharged into thebiopsy site 85 as shown in FIG. 9C. The device 80 has an elongatedplunger or piston 86 slidably disposed within the tube 81 for pushingone or more markers 84 through the petalled distal end by pressing onthe knob 87 on the proximal end of the shaft 86. The orientation of thebody 88 on the shaft 86 gives the operator an indication of theorientation of the shaped distal end 89.

FIG. 10 illustrates an alternative marker 90 which has an elongatedcylindrically shaped body of gel 91 surrounded with a metallic band 92which is preferably formed of radiopaque material. The band 92 mayconpletely or only partially surround the body of gel 91.

In any of the above-described embodiments of the invention, the markerbody (and/or the optional encapsulating element) may include an adhesivecomponent to cause the marker body (or encapsulating element) to adhereto adjacent tissue within the biopsy site. The adhesive component maycomprise a biocompatible adhesive, such as a polyurethane, polyacryliccompound, polyhydroxymethacrylate, fibrin glue (e.g., Tisseal™),collagen adhesive, or mixtures thereof.

While particular forms of the invention have been illustrated anddescribed, it will be apparent that various modifications can be madewithout departing from the spirit and scope of the invention.Accordingly, it is not intended that the invention be limited to thespecific embodiments illustrated. It is therefore intended that thisinvention to be defined by the scope of the appended claims as broadlyas the prior art will permit, and in view of the specification if needbe.

1. An intracorporeal site marker for marking a selected site withintissue of a patient's body, comprising: (a) an ultrasound detectablebody including boundaries having a high contrast in acoustical impedancewhen the marker is placed in tissue of the selected site, so as toefficiently reflect ultrasound during ultrasound imaging; and (b) a bodyshape which is recognizably artificial when the marker is subject toultrasound or X-ray imaging, so as to be readily distinguishable frombiological features within the tissue site. 2-41. (Canceled)
 42. Amarker delivery system, comprising: an elongated marker delivery tubewhich has a closed distal end, at least one slit in the closed distalend and an inner lumen extending to and in fluid communication with theat least one slit therein; a piston slidably disposed within the innerlumen of the marker delivery tube; and a plurality of biopsy sitemarkers slidably disposed within the inner lumen of the marker deliverytube distal to the piston disposed therein.
 43. The marker deliverysystem of claim 42, further comprising an outer cannula configured toreceive said elongated marker delivery device and direct the closeddistal end thereof to a desire location.
 44. A remotely detectablemarker for marking a selected intracorporeal site within a patient,comprising a sintered, ultrasound detectable body which is formed atleast in part of metallic material, which has boundaries with a highcontrast in acoustical impedance when the marker is placed at anintracorporeal site to facilitate ultrasound detection; and which has abody shape which is recognizable as artificial.
 45. The intracorporealsite marker of claim 44 wherein the body is remotely detectable byultrasound or X-ray.
 46. The intracorporeal site marker of claim 44wherein the metallic material is selected from the group consisting ofstainless steel, titanium, platinum, palladium and alloys thereof. 47.The intracorporeal site marker of claim 44 wherein the metallic materialis titanium.
 48. The intracorporeal site marker of claim 44 wherein themetallic material is 316 stainless steel.
 49. The intracorporeal sitemarker of claim 44 wherein the body is cylindrical in shape.
 50. Theintracorporeal site marker of claim 47 wherein the cylindrical shape hasa diameter of about 0.5 to about 5 mm and a length of at least onediameter.
 51. The intracorporeal site marker of claim 48 wherein thecylindrical shape has a length of up to 10 diameters.
 52. Theintracorporeal site marker of claim 48 wherein the cylindrical shape hasa length of about 5 to about 7 diameters.
 53. The intracorporeal sitemarker of claim 48 wherein the cylindrically shaped body is a helicallyshaped coil.
 54. The intracorporeal site marker of claim 44 wherein thebody has a spherical shape.
 55. The intracorporeal site marker of claim54 wherein the spherically shaped body has a diameter of about 1 toabout 4 mm.